What is Stereotaxis's other commercial liabilities?

Stereotaxis (STXS) reported other commercial liabilities of $1.48M in Q1 2026.

How has Stereotaxis's other commercial liabilities changed year-over-year?

Stereotaxis's other commercial liabilities decreased by 49.5% year-over-year, from $2.93M to $1.48M.

What is the long-term trend for Stereotaxis's other commercial liabilities?

Over 5 years (2020 to 2025), Stereotaxis's other commercial liabilities has grown at a -8.4% compound annual growth rate (CAGR), from $3.21M to $2.07M.

Stereotaxis STXS Other Commercial Liabilities

Other Commercial Liabilities at other companies

Boston ScientificBSX

——

ITG

Integer HoldingsITGR

——

Merit Medical SystemsMMSI

——

IAR

Integra LifeSciencesIART

——

Neuropace, Inc.NPCE

——

NeuroneticsSTIM

——

Other financials

Income statement

See full

Revenue$6.3M-15.8%

Gross profit$3.8M-6.6%

Operating income-$6.0M-0.9%

Net income-$5.9M-0.7%

EPS (diluted)-$0.06+14.3%

Balance sheet

See full

Cash & equivalents$14.6M+36.7%

Total debt$5.3M-10.0%

Total equity$14.4M+399%

Total assets$54.0M+18.2%

Cash flow

See full

Operating cash flow-$3.4M-93.5%

CapEx$79.0K—

Free cash flow-$3.5M—

Valuation

See full

Market cap$168.11M-11.6%

Enterprise value$158.77M-15.9%

P/S5.4×-0.6×

Profitability

See full

Gross margin53.9%+0.5pp

Operating margin-71%-14.0pp

Net margin-69.5%-13.7pp

FCF margin-35.5%-2.4pp

Returns & leverage

See full

Return on equity-251.5%-29.9pp

Debt / equity0.4×-1.7×

Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stereotaxis's other commercial liabilities?: Stereotaxis (STXS) reported other commercial liabilities of $1.48M in Q1 2026.
How has Stereotaxis's other commercial liabilities changed year-over-year?: Stereotaxis's other commercial liabilities decreased by 49.5% year-over-year, from $2.93M to $1.48M.
What is the long-term trend for Stereotaxis's other commercial liabilities?: Over 5 years (2020 to 2025), Stereotaxis's other commercial liabilities has grown at a -8.4% compound annual growth rate (CAGR), from $3.21M to $2.07M.